Navigation Links
American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD

Endorsed by the American Academy of Child and Adolescent Psychiatry, the American College of Cardiology, Children and Adults with Attention-Deficit/Hyperactivity Disorder and the National Initiative for Children's Healthcare Quality

DALLAS, May 16 /PRNewswire-USNewswire/ -- The American Heart Association released on April 21, 2008 a statement about cardiovascular evaluation and monitoring of children receiving drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a result of language in the news release and the statement as published, there have been conflicting interpretations of the recommendations regarding the use of an electrocardiogram (ECG) in assessing children with ADHD who may need treatment with medications. The purpose of this joint advisory of the American Academy of Pediatrics (AAP) and the American Heart Association (AHA) is to clarify the recommendations.

-- The scientific statement included a review of data that show children

with heart conditions have a higher incidence of ADHD.

-- Because certain heart conditions in children may be difficult (even, in

some cases, impossible) to detect, the AAP and AHA feel that it is

prudent to carefully assess children for heart conditions who need to

receive treatment with drugs for ADHD.

-- Obtaining a patient and family health history and doing a physical exam

focused on cardiovascular disease risk factors (Class I recommendations

in the statement) are recommended by the AAP and AHA for assessing

patients before treatment with drugs for ADHD.

-- Acquiring an ECG is a Class IIa recommendation. This means that it is

reasonable for a physician to consider obtaining an ECG as part of the

evaluation of children being considered for stimulant drug therapy, but

this should be at the physician's judgment, and it is not mandatory

to obtain one.

-- Treatment of a patient with ADHD should not be withheld because an ECG

is not done. The child's physician is the best person to make the

assessment about whether there is a need for an ECG.

-- Medications that treat ADHD have not been shown to cause heart

conditions nor have they been demonstrated to cause sudden cardiac

death. However, some of these medications can increase or decrease

heart rate and blood pressure. While these side effects are not usually

considered dangerous, they should be monitored in children with heart

conditions as the physician feels necessary.

An erratum to the statement has been developed to clarify the language and to assure that the intent is clear to all readers. This is available at: DC1.

This clarification has been endorsed by the American Academy of Child and Adolescent Psychiatry, the American College of Cardiology, Children and Adults with Attention-Deficit/Hyperactivity Disorder and the National Initiative for Children's Healthcare Quality.

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting
2. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
3. Statement from Larry Minnix, President & CEO American Association of Homes and Services for the Aging, On the Government Accountability Offices (GAO) Nursing Home Oversight Report
4. American Red Cross Vindicated in J&J Lawsuit
5. The American Red Cross Commits $10 Million to Assist China Earthquake Survivors
6. Americans must consider cost and effectiveness when comparing and choosing medical interventions
7. American Red Cross Supports China and Myanmar Relief Efforts
8. American Diabetes Wholesale Launches Affiliate Program
9. The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines
10. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
11. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... wound care advancements to physician colleagues, skilled nursing facility medical directors and other ... Treacherous Waters of Wound Care." , "At many of these conferences we get ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: